Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | CCR9 | P51686 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14459525 | 0.82 | POLB (0.70) | FFAR4POLBKDM4ELMNAALDH1A1 | |
| SCHEMBL152522 | 0.77 | SMN1; SMN2 (0.65) | RAB9AKDM4ELMNAALDH1A1 | |
| SCHEMBL15880397 | 0.77 | SMN1; SMN2 (0.56) | FFAR4NPC1RAB9APOLBKDM4E | |
| SCHEMBL16235227 | 0.76 | CCR9 (0.54) | FFAR4CCR9SLC40A1 | |
| SCHEMBL1094138 | 0.76 | POLB (0.55) | POLBKDM4ELMNAALDH1A1 | |
| SCHEMBL26536628 | 0.76 | FFAR4 (0.51) | FFAR4CCR9SLC40A1PTGDR2FBP1 | |
| SCHEMBL28409808 | 0.76 | SMN1; SMN2 (0.63) | RAB9AKDM4ELMNAALDH1A1 | |
| SCHEMBL26530281 | 0.73 | SCN3A (0.71) | KDM4ELMNASCN9AALDH1A1 | |
| SCHEMBL2447504 | 0.72 | FFAR4 (0.60) | FFAR4L3MBTL1LMNAFBP1 | |
| SCHEMBL6292016 | 0.72 | SLC40A1 (0.55) | SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | FFAR4 2391/4885CCR9 2746/4885NPC1 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.